Orally exposed uninfected individuals have systemic anti-HIV responses associating with partners' viral load

AIDS

Volumn 24, Issue 1, 2010, Pages 35-43

  Hasselrot, Klara ^a   Bratt, Göran ^b   Hirbod, Taha ^a   Säberg, Pär ^b   Ehnlund, Mariethe ^a   Lopalco, Lucia ^c   Sandström, Eric ^b   Broliden, Kristina ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b STOCKHOLM SÖDER HOSPITAL   (Sweden)

^c SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Exposed uninfected individuals; HIV 1; Immunoglobulin A; Men who have sex with men; Neutralization

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CHEMOKINE RECEPTOR CCR5; IMMUNOGLOBULIN A ANTIBODY;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGLOBULIN BLOOD LEVEL; MALE; MALE HOMOSEXUAL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PREVALENCE; PRIORITY JOURNAL; QUESTIONNAIRE; RISK FACTOR; SEXUAL BEHAVIOR; VIRUS ENVELOPE; VIRUS ISOLATION; VIRUS LOAD; VIRUS NEUTRALIZATION; WESTERN BLOTTING;

EID: 73649143882     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3283329853     Document Type: Article

References (30)

1. Miyazawa M, Lopalco L, Mazzotta F, Lo Caputo S, Veas F, Clerici M. The 'immunologic advantage' of HIV-exposed ser-onegative individuals. AIDS 2009; 23:161-175.
2. Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, Horuk R, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996; 86:367-377.
3. Lacap PA, Huntington JD, Luo M, Nagelkerke NJ, Bielawny T, Kimani J, et al. Associations of human leukocyte antigen DRB with resistance or susceptibility to HIV-1 infection in the Pumwani Sex Worker Cohort. AIDS 2008; 22:1029-1038. (Pubitemid 351769741)
4. Gonzalez E, Kulkarni H, Bolivar H, Mangano A, Sanchez R, Catano G, et al. The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility. Science 2005; 307:1434-1440.
5. Arenzana-Seisdedos F, Parmentier M. Genetics of resistance to HIV infection: role of co-receptors and co-receptor ligands. Semin Immunol 2006; 18:387-403.
6. Suy A, Castro P, Nomdedeu M, Garcia F, Lopez A, Fumero E, et al. Immunological profile of heterosexual highly HIV-ex-posed uninfected individuals: predominant role of CD4 and CD8 T-cell activation. J Infect Dis 2007; 196:1191-1201.
7. R responses. J Clin Invest 2001; 107:341-349.
8. Baker BM, Block BL, Rothchild AC, Walker BD. Elite control of HIV infection: implications for vaccine design. Expert Opin Biol Ther 2009; 9:55-69.
9. Pilcher CD, Tien HC, Eron JJ Jr, Vernazza PL, Leu SY, Stewart PW, et al. Brief but efficient: acute HIV infection and the sexual transmission of HIV. J Infect Dis 2004; 189:1785-1792.
10. Willberg CB, McConnell JJ, Eriksson EM, Bragg LA, York VA, Liegler TJ, et al. Immunity to HIV-1 is influenced by continued natural exposure to exogenous virus. PLoS Pathog 2008; 4:e1000185.
11. Kulkarni PS, Butera ST, Duerr AC. Resistance to HIV-1 infection: lessons learned from studiesof highly exposed persistently seronegative (HEPS) individuals. AIDS Rev 2003; 5:87-103.
12. Hasselrot K, Saberg P, Hirbod T, Soderlund J, Ehnlund M, Bratt G, et al. Oral HIV-exposure elicits mucosal HIV-neutralizing antibodies in uninfected men who have sex with men. AIDS 2009; 23:329-333.
13. Kindberg E, Hejdeman B, Bratt G, Wahren B, Lindblom B, Hinkula J, Svensson L. A nonsense mutation (428G!A) in the fucosyltransferase FUT2 gene affects the progression of HIV-1 infection. AIDS 2006; 20:685-689.
14. Devito C, Hinkula J, Kaul R, Kimani J, Kiama P, Lopalco L, et al. Cross-clade HIV-1-specific neutralizing IgA in mucosal and systemic compartments of HIV-1-exposed, persistently sero-negative subjects. J Acquir Immune Defic Syndr 2002; 30:413-420.
15. Devito C, Hinkula J, Kaul R, Lopalco L, Bwayo JJ, Plummer F, et al. Mucosal and plasma IgA from HIV-exposed seronegative individuals neutralize a primary HIV-1 isolate. AIDS 2000; 14:1917-1920.
16. Albert J, Abrahamsson B, Nagy K, Aurelius E, Gaines H, Ny-strom G, Fenyo EM. Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera. AIDS 1990; 4:107-112.
17. Hirbod T, Kaul R, Reichard C, Kimani J, Ngugi E, Bwayo JJ, et al. HIV-neutralizing immunoglobulin A and HIV-specific proliferation are independently associated with reduced HIV acquisition in Kenyan sex workers. AIDS 2008; 22:727-735.
18. Hirbod T, Reichard C, Hasselrot K, Soderlund J, Kimani J, Bwayo JJ, et al. HIV-1 neutralizing activity is correlated with increased levels of chemokines in saliva of HIV-1-exposed uninfected individuals. Curr HIV Res 2008; 6:28-33.
19. Clerici M, Barassi C, Devito C, Pastori C, Piconi S, Trabattoni D, et al. Serum IgA of HIV-exposed uninfected individuals inhibit HIV through recognition of a region within the alpha-helix of gp41. AIDS 2002; 16:1731-1741.
20. Lucotte G, Dieterlen F. More about the Viking hypothesis of origin of the delta32 mutation in the CCR5 gene conferring resistance to HIV-1 infection. Infect Genet Evol 2003; 3:293-295.
21. Powers KA, Poole C, Pettifor AE, Cohen MS. Rethinking the heterosexual infectivity of HIV-1: a systematic review and meta-analysis. Lancet Infect Dis 2008; 8:553-563.
22. Vittinghoff E, Douglas J, Judson F, McKirnan D, MacQueen K, Buchbinder SP. Per-contact risk of human immunodeficiency virus transmission between male sexual partners. Am J Epidemiol 1999; 150:306-311.
23. Zhu T, Corey L, Hwangbo Y, Lee JM, Learn GH, Mullins JI, McElrath MJ. Persistence of extraordinarily low levels of genetically homogeneous human immunodeficiency virus type 1 in exposed seronegative individuals. J Virol 2003; 77:6108-6116.
24. Hessell AJ, Poignard P, Hunter M, Hangartner L, Tehrani DM, Bleeker WK, et al. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat Med 2009; 15:951-954.
25. Hirbod T, Broliden K, Kaul R. Genital immunoglobulin A and HIV-1 protection: virus neutralization versus specificity. AIDS 2008; 22:2401-2402.
26. Sturmer M, Doerr HW, Berger A, Gute P. Is transmission of HIV-1 in nonviraemic serodiscordant couples possible? Antivir Ther 2008; 13:729-732.
27. Mazzoli S, Lopalco L, Salvi A, Trabattoni D, Lo Caputo S, Semplici F, et al. Human immunodeficiency virus (HIV)-spe-cific IgA and HIV neutralizing activity in the serum of exposed seronegative partners of HIV-seropositive persons. J Infect Dis 1999; 180:871-875.
28. Belyakov IM, Ahlers JD. Functional CD8(R) CTLs in mucosal sites and HIV infection: moving forward toward a mucosal AIDS vaccine. Trends Immunol 2008; 29:574-585.
29. Broliden K, Haase AT, Ahuja SK, Shearer GM, Andersson J. Introduction: Back to basics-mucosal immunity and novel HIV vaccine concepts. J Intern Med 2009; 265:5-17.
30. Brave A, Hallengard D, Schroder U, Blomberg P, Wahren B, Hinkula J. Intranasal immunization of young mice with a multigene HIV-1 vaccine in combination with the N3 adjuvant induces mucosal and systemic immune responses. Vaccine 2008; 26:5075-5078.